Introduction
Pneumocystis carinii is an important cause of morbidity and mortality in the immunocompromised host. Although the screening of anti-P. carinii agents has been hampered by the difficulty of cultivating the organism in vitro, several new compounds are being extensively evaluated and some are now available to treat the infection clinically. 1, 2 In recent years many antimicrobial cationic peptides have been isolated from a wide range of animal, plant and bacterial species. [3] [4] [5] [6] [7] [8] [9] These molecules can be divided into several classes based on amino acid sequences and secondary structure. Some of these compounds consist of small, basic peptides configured as single, amphipathic -helices. 10 Other peptides are characterized structurally by two -helices joined by a region containing glycine and proline, and others consist of cationic peptides containing three intramolecular disulphide bonds. 11, 12 Additional kinds of peptides include the proline-rich molecules, the tryptophan-rich molecules and the polymyxin-related compounds with a single intramolecular disulphide bond. 13 These compounds provide a host-defence system to combat infections: they are thought to function through the formation of ion channel pores spanning the membranes of bacteria, fungi, erythrocytes, artificial lipid bilayers and protozoa. [14] [15] [16] Drugs that inhibit folic acid synthesis have long been a mainstay for the treatment of P. carinii infections in the immunocompromised patient. The dihydrofolate reductase inhibitors (DHFRs), such as pyrimethamine, trimethoprim and diaveridine, have only a static effect on parasite growth and frequently cause adverse effect in AIDS patients. Although the antifolate combination of DHFR and sulphonamide or sulphone acts synergically against P. carinii, new combinations are needed. 1, 17 Several studies have been performed to investigate new synergic drug combinations. Recent reports, for example, provide evidence that macrolides combined with sulphonamides have exhibited high in-vitro and in-vivo activity against P. carinii. 18 To study new combinations for the treatment or prevention of P. carinii infections, we investigated the in- 
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Materials and methods
Parasite preparation and cell culture
These procedures have been described in detail previously. 19 Briefly, six clinical isolates of P. carinii were obtained from bronchoalveolar lavages of six AIDS patients who had not received prior anti-P. carinii therapy. Specimens were homogenized in an equal volume of phosphate-buffered saline (PBS). The homogenate was centrifuged (1800g for 15 min) and the pellet was resuspended in physiological saline. Contaminating bacteria were partially eliminated by four washes in 10 mL of physiological saline followed by incubation in PBScontaining ampicillin (2000 mg/L) and streptomycin (2000 mg/L) for 4 h at 37°C. Organisms were pelleted by centrifugation (1800g for 20 min), and resuspended in Dulbecco's modified Eagle's medium (DMEM) (BioWhittaker, Walkersville, MD, USA). Cysts were counted using methenamine silver stain and nuclei were counted using Giemsa stain before being used for culture. The final inoculum contained 10 3 -10 4 P. carinii organisms/mL. The human lung epithelial cell line A-549 was maintained in 96-well tissue culture plates (Becton Dickinson Italia, Milan, Italy). Culture was initiated by adding 0.1 mL of inoculum to an adherent layer of 50-70% confluent A549 cells. After incubation for 4 h at 37°C in 5% CO 2 to allow attachment and penetration of sporozoites, the monolayers were washed with DMEM to remove noninvasive sporozoites, residual cysts and non-adherent epithelial cells, and 0.2 mL of new growth medium with or without antimicrobial agents was added. Infected cell cultures were kept at 37°C in 5% CO 2 throughout the study.
Drugs
All drugs were obtained from Sigma-Aldrich, Milan, Italy, unless otherwise stated.
Cecropin P1, magainin II, indolicidin and ranalexin were solubilized in phosphate-buffered saline (PBS, pH 7.2) yielding 1 mM stock solution. Azithromycin (Pfiz e r / R o e r i g , Rome, Italy), clarithromycin (Abbott, Rome, Italy), roxithromycin (Roussel Pharma, Milan, Italy), trimethoprim, diaveridine and pyrimethamine were dissolved in 50% methanol : 50% acetone at a concentration of 1 mg/mL. Sulphamethoxazole was dissolved in dimethylsulphoxide at 1 mg/mL. Solutions of drugs were made fresh on the day of assay or stored at -80°C in the dark for short periods.
Susceptibility testing
Serial dilutions of each drug were prepared in DMEM such that the addition of 100 L of each dilution to a culture plate produced the required final concentrations. Cecropin P1, magainin II, indolicidin and ranalexin were each tested at the following concentrations: 0.2, 2 and 20 M. Azithromycin, clarithromycin and roxithromycin were each tested at concentrations of 1 and 4 mg/L. Trimethoprim, diaveridine and pyrimethamine were each tested at concentrations of 0.05 and 0.5 mg/L. Trimethoprim-sulphamethoxazole (TMP-SMX), used as a reference drug combination, was tested at concentrations of 0.8 and 3.2 mg/L, plus 4 and 16 mg/L, respectively. Preliminary experiments indicated that the final concentrations of methanol, acetone and dimethylsulphoxide used in the dilution of drugs did not inhibit the growth of P. carinii. In experiments to test drug interactions, the three above-mentioned concentrations of each peptide were added to the highest concentration of each other agent. Antibiotic-free plates were used as controls in the study. Experiments were performed in triplicate.
P. carinii was added at a concentration of 10 2 -10 3 organisms/well. The monolayers were incubated at 37°C in a 5% CO 2 atmosphere. After 72 h, samples of supernatant were withdrawn from each triplicate well, and trophozoite and cyst counts were performed by Giemsa and methenamine silver staining.
Analysis of results
The anti-P. carinii activity of each agent and combination was evaluated by counting parasites from plates with antimicrobial-supplemented medium compared with control plates without drugs. The average number P. carinii parasites per mL S.D. was calculated by counting 50 oilimmersion fields ( 1000 magnification) of each of three slides. The 50% and 90% inhibitory concentrations (IC 50 and IC 90 , respectively) were defined as the concentrations required to produce 50% and 90% reduction, respectively, in the mean cyst or nucleus counts compared with controls without drug after 72 h incubation in the presence of drugs.
Results
In control plates without drugs, a 3-to 4-fold increase in the number of P. carinii nuclei occurred over 3 days. The average number of parasites grown in the absence of antibiotic was 47.3 (range 20-66) when calculated by counting 50 oil-immersion fields.
All lytic peptides tested were similarly effective against P. carinii with a higher activity against trophozoites than cysts (data not shown (Table I) . To assess any potential synergic effect, we performed experiments in which both inhibitory concentrations and non-inhibitory concentrations of each agent were tested. Our data showed that the activity of lytic peptides remained virtually unchanged when they were tested either alone or in combination with macrolides and DHFRs, with the exception of ranalexin, which enhanced its activity when it was combined with non-inhibitory concentrations of macrolides (4 mg/L) Cecropin  20  2  20  20  Cecropin diaveridine  2  2  20  20  Cecropin pyrimethamine  20  2  20  20  Cecropin trimethoprim  20  2  20  20  Cecropin azithromycin  2  2  20  20  Cecropin clarithromycin  2  2  20  20  Cecropin roxithromycin  20  2  20  20  Magainin  20  2  20  20  Magainin diaveridine  2  2  20  20  Magainin pyrimethamine  2  2  20  20  Magainin trimethoprim  2  2  20  20  Magainin azithromycin  2  2  20  20  Magainin clarithromycin  2  2  20  20  Magainin roxithromycin  2  2  20  20  Indolicidin  20  20  20  20  Indolicidin diaveridine  20  2  20  20  Indolicidin pyrimethamine  2  2  20  20  Indolicidin trimethoprim  20  2  20  20  Indolicidin azithromycin  2  2  20  20  Indolicidin clarithromycin  2  2  20  20  Indolicidin roxithromycin  20  2  20  20  Ranalexin  20  2  20  20  Ranalexin diaveridine  2  2  20  20  Ranalexin pyrimethamine  2  2  20  20  Ranalexin trimethoprim  2  2  20  20  Ranalexin azithromycin  2  2  20  20  Ranalexin clarithromycin  2  2  20  20  Ranalexin roxithromycin  2  2  20 having shown a constant 100% reduction of either cyst or trophozoite counts (Tables II-V) . This phenomenon was particularly evident when the peptides (2 M) were tested in combination with macrolides (4 mg/L). We observed a cysts/trophozoites reduction in the range 77.3-85.1% when ranalexin 2 M was combined with macrolides. Finally, the IC 50 and IC 90 values showed that lytic peptides (alone or in combination with macrolides) were as effective as TMP-SMX but only at the highest concentration tested. These results are summarized in Table I .
Discussion
In this study a quantitative system to evaluate the in-vitro anti-P. carinii activity of four lytic peptides, alone and combined with macrolides or DHFRs, has been developed. The A549 line and 96-well plates were used to evaluate several agents with smaller amounts of drugs. As control drug we used the combination TMP-SMX, which has proved to be extremely effective in treating P. carinii pneumonia. The parasite growth was assessed by quantifying cysts and trophozoites in the supernatant after 72 h incubation at 37°C in a 5% CO 2 atmosphere. Preliminary experiments indicated that P. carinii can be seen both in the supernatant and attached to the cell monolayer. 19 Antimicrobial peptides comprise a diverse class of molecules used in host defence by plants, insects and animals: they have been found in plants, insects, fish, crustaceans, amphibians, birds and mammals, including humans. Their physiological role has not been defined. These peptides, because of their small size (11-35 amino acids) and antimicrobial potency, may have therapeutic potential in the treatment of infections in humans. In mammals, including humans, they are the predominant protein species in the neutrophil and they are also found on the surface of the tongue, trachea, lungs and upper intestine and are thought to be a major antibacterial defence on mucosal surfaces. 9 It has been suggested that the mode of action of these compounds on the membranes of bacteria, fungi, protozoa and artificial lipid bilayers may be similar and involves the formation of ion-channel pores spanning the membranes without requiring a specific target receptor; the peptides rapidly depolarize the bacterial cell membrane and uncouple oxidative respiration in mammalian mitochondria. 2 0 Cecropin P1, magainin II and indolicidin showed high activity against Gram-negative bacteria, such as Escherichia coli, Salmonella typhimurium and Acinetobacter calcoaceticus with only moderate or no activity against Gram-positive bacteria. 8, 9, 21 In our experiments these peptides were shown to be effective against P. carinii, but their activity was scarcely On the other hand, ranalexin had its activity enhanced upon combination with macrolides. The mechanism of this synergy between ranalexin and macrolides appears to be complex. Ranalexin is a peptide recently isolated from the skin of the American bullfrog, Rana catesbiana. 13 It contains 20 amino acids, two of which are cysteines; these cysteines were found to form an intramolecular disulphide bond. While the primary amino acid sequence of ranalexin is unique, it shares remarkable structural similarity with the polymyxins, a class of membrane-active antibiotics. The polymyxins are amphipathic molecules composed of ten amino acids, with a fatty acid attached to the amino terminus in an amide linkage; this fatty acid is crucial for antimicrobial activity, since its removal abolishes antimicrobial activity. 13 Like the polymyxins, ranalexin is an amphipathic compound, with a cationic heptapeptide ring at its carboxyl terminus and a hydrophobic region at its amino terminus. Just as removal of the fatty acid from polymyxins eliminates their antimicrobial activity, analogues of ranalexin with one to four of the hydrophobic amino acids deleted from the amino terminus have no antimicrobial activity. 13 Polymyxin-like peptides have both direct antibacterial activity and membranepermeabilizing activity and present properties of synergy with lipophilic and amphiphilic agents such as rifampicin, macrolides, fusidic acid and novobiocin. 21 Even though polymyxin-like peptides disintegrate the biological membranes and yield to uncoupling of the oxidative respiration, it is probably only the membrane damage that allows a synergic action between peptides and other lipophilic or amphiphilic antibiotic agents. Recent reports demonstrate that polymyxin-like peptides allow maximal entry of several hydrophobic substrates, such as macrolides, inside the cell. 21, 22 The lytic peptides are fascinating compounds: our results show that they are effective in inhibiting P. carinii at concentrations that are not toxic for the monolayer, and several reports describe their antibacterial activity. This fact makes these compounds potentially very valuable as an adjuvant for antimicrobial chemotherapy. They represent a conserved theme in host antimicrobial defences throughout nature and potentially provide the first new structural class of antimicrobial agents in three decades.
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Interestingly, ranalexin and other polymyxin-related peptides might find value as microbiological tools in various fields of basic and applied research. Many molecules and probes used in studies of bacterial physiology and biochemistry are hydrophobic and cannot penetrate the outer membrane, but can be expected to cross a membrane damaged by the lytic peptides. 
